STOK Stock Forecast: Stoke Therapeutics, Inc. Price Predictions for 2026-2027
The 14 Wall Street analysts covering Stoke Therapeutics, Inc. hold a median 12-month price target of $43 — +60.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Stoke Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (77): The share price has been relatively steady.
Growth (15): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
STOK stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on STOK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +60.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2026 | JP Morgan | Reinstates | Overweight | $40 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Buy | $60 → $58 |
| 4 Aug 2026 | Chardan Capital | Maintains | Buy | $35 |
| 4 Aug 2026 | Guggenheim | Reiterates | Buy | $60 |
| 4 Aug 2026 | Wedbush | Maintains | Outperform | $38 → $40 |
| 13 July 2026 | Goldman Sachs | Initiates | Buy | $44 |
| 11 May 2026 | BTIG | Reiterates | Buy | — |
| 20 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 Mar 2026 | BTIG | Reiterates | Buy | — |
| 18 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 18 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 17 Mar 2026 | Needham | Maintains | Buy | — |
| 17 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 24 Feb 2026 | Wolfe Research | Initiates | Outperform | — |
| 12 Jan 2026 | Wedbush | Maintains | Outperform | — |
| 5 Jan 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 15 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Nov 2025 | BTIG | Reiterates | Buy | — |
| 5 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for STOK.
This page is one stock. Monday covers all of them.
STOK appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
STOK vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Stoke Therapeutics, Inc. returned −4.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
STOK analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 64.1×
- Price / book
- 5.1×
- EV / EBITDA
- —
Cheaper than 4% of US stocks
Cheaper than 18% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −73.6%
- Return on assets
- −42.0%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Stoke Therapeutics, Inc. has a market value of $1.8B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $27.6M. The latest quarter shrank 32.5% year on year.
Net income over the same four quarters: −$207.9M, a −753.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$180.7M.
Stoke Therapeutics, Inc. employs 170 people — $162K of revenue per employee.
Data provided by Twelve Data
STOK and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at STOK’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Stoke Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about STOK
What is the STOK stock price forecast for 2026-2027?
The 14 Wall Street analysts covering Stoke Therapeutics, Inc. have a median 12-month price target of $43, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is STOK stock a buy right now?
Of the 14 analysts covering Stoke Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stoke Therapeutics, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank STOK?
As at 21 Nov 2026, Stoke Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).
Will STOK stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts implies +60.4% from the last close, and Ticker Nerd's factor model ranks Stoke Therapeutics, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the STOK stock forecast for 2030?
No analyst covering Stoke Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STOK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.
How has STOK stock performed over the past year?
Stoke Therapeutics, Inc. returned -4.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Stoke Therapeutics, Inc. do?
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production.
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production. The company’s portfolio centers on precision therapies for rare neuromuscular, neurological, and other haploinsufficiency-related conditions, with a strong emphasis on antisense oligonucleotide approaches and targeted gene output modulation. Stoke Therapeutics operates in the genetic medicines and rare disease markets, where its research platform supports the discovery and development of treatments intended to restore healthier levels of naturally occurring proteins. Headquartered in Bedford, Massachusetts, Stoke Therapeutics plays a specialized role in advancing novel therapeutic approaches for patients with complex inherited diseases.
CEO Mr. Ian F. Smith A.C.A., C.P.A. · 170 employees · United States · https://www.stoketherapeutics.com